FDA approves Riabni ,a rituximab biosimilar ,for moderate to severe rheumatoid arthritis.
Amgen announced that the FDA has approved Riabni (rituximab-arrx), a biosimilar to Rituxan, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. Riabni is already approved for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (also called Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA).
Riabni, a CD20-directed cytolytic antibody, was proven to be highly similar to, with no clinically meaningful differences in safety or efficacy from, Rituxan (rituximab) based on totality of evidence, which included comparative analytical, non-clinical and clinical data.
Related news and insights
Data from the NP30179 study of glofitamab have been submitted by Genentech/Roche for approval to the European Medicines Agency (EMA), and submissions to additional health authorities worldwide, including to the FDA, are planned this year.